Genentech

LUCENTIS

ASP | WAC | AWP at the HCPCS Unit

Manufacturer:

Genentech

Lucentis HCPCS:

J2778

HCPCS Code Descriptor:

Injection, ranibizumab, 0.1 mg

Category:

J Code

Lucentis NDCs:

50242-0080-03, 50242-0082-03

Primary Type:

Opthalmic

Generic/Specialty Status:

Single-Source

Package Type:

Multiple

Route of Administration:

Intraocular

Lucentis CPT Codes:

-67028 - Intravitreal injection of a pharmacologic agent (separate procedure)

Some of the most common CPT administration codes for 'buy and bill' drugs can be found at the following link:

Potential NDC Listing Errors:

We have not identified any potential errors with the NDCs mapped to this HCPCS code.

About Lucentis:

LUCENTIS is an Opthalmic drug manufactured by Genentech and administered via the Intraocular route of administration. The J Code: J2778 is aligned to the drug LUCENTIS.

Lucentis, or Ranibizumab, is a blood vessel growth inhibitor. Lucentis is used to treat wet age-related macular degeneration, also known as AMD. Lucentis is injected into the eye to help slow vision loss from AMD. It can also be used to treat conditions such as diabetic eye disease, retinal vein occlusion, and other retina-related issues. Lucentis works by slowing or stopping the growth of abnormal blood vessels in the back of the eye, which may otherwise leak and affect vision.

ACCESS PRICING AND MORE BY REGISTERING

J2778 Added Date:

January 1, 2008

J2778 Effective Date:

January 1, 2008

J2778 Termination Date:

HCPCS Active

Lucentis billing and coding information can be found through Genentech at the link below:
Lucentis patient assistance information can be found through Genentech at the URL: https://www.gene.com/patients/patient-foundation
LUCENTIS prescribing information can be found at the link below:
Information regarding LUCENTIS’s side effects can be found at MedlinePlus